Development of neuraminidase inhibitors as anti-influenza virus drugs

Drug Development Research

Volumn 46, Issue 3-4, 1999, Pages 176-196

  Varghese, Joseph N ^a,b  

^a CSIRO   (Australia)

^b Biomolecutar Research Institute   (Australia)

Author keywords

Relenza(TM); Sialidase; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; ENZYME INHIBITOR; FLAVONOID; INFLUENZA VACCINE; KAMPO; PLANT EXTRACT; RIBAVIRIN; RIMANTADINE; SIALIC ACID DERIVATIVE; VIRUS SIALIDASE; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG DESIGN; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; HUMAN; INFLUENZA; INFLUENZA VIRUS; INTRANASAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RESPIRATORY TRACT INFECTION; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS INFECTION; VIRUS INHIBITION;

EID: 0032996584     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199903/04)46:3/4<176::AID-DDR4>3.0.CO;2-6     Document Type: Article

References (146)

1. Air GM, Laver WG. 1995. Red cells bound to influenza virus N9 neuraminidase are not released by the N9 neuraminidase activity. Virology 211:278-284.
2. Alexander DJ. 1986. Avian diseases - historical aspects. In: Proceedings of the 2nd International Symposium on Avian Influenza. Richmond, VA: U.S. Animal Heath Assosiation. p 4-13.
3. Aoki F, Osterhaus A, Rimmelzwaan, Kinnersley N, Ward E 1998. Oral GS4104 successfully reduces duration and severity of naturally acquired influenza. San Diego: ICAAC 24-27 Sept. (Abstr. LB-5).
4. Baker NJ, Gandhi SS. 1976. Effect of Ca++ on the stability of influenza virus neuraminidase. Arch Virol 52:7-18.
5. Baker AT, Varghese JN, Laver WG, Air GM, Colman PM. 1987. The three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins 1:111-117.
6. Beveridge WI. 1977. Influenza: the last great plague. London: Heinemann.
7. Blick TJ, Tiong T, Sahasrabudhe A, Varghese JN, Colman PM, Hart GJ, Bethell RC, McKimm-Breschkin JL. 1995. Generation and characterization of an influenza virus variant with decreased sensitivity to the neuraminidase specific inhibitor 4-guanidino-Neu5Ac2en. Virology 214:475-484.
8. Blok J, Air GM, Laver WG, Ward CW, Lilley GG, Woods EF, Roxburgh CM, Inglis AS. 1982. Studies on the size, chemical composition and partial sequence of the neuraminidase (NA) from type A influenza virus show that the N-terminal region of the NA is not processed and serves to anchor the NA in the viral membrane. Virology 119:109-121.
9. Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG, Air GM. 1993. Three dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid J Mol Biol 232:1069-1083.
10. Both GW, Sleigh MJ, Cox NJ, Kendal AP. 1983. Antigenic drift in influenza virus H3 haemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol 48:52-60.
11. Bucher DJ, Palese P. 1975. The biologically active proteins of influenza virus neuraminidase. In: Kilbourne ED, editor. Influenza virus and influenza. New York: Academic Press, p 83-123.
12. Burmeister WP, Ruigrok RWH, Cusack S. 1991. The 2.2Å resolution crystal structure of influenza B neuraminidase and its complex to sialic acid. EMBO J 11:49-56.
13. Burmeister WP, Henrissat B, Bosso C, Cusack S, Ruigrok RWH. 1993. Influenza B virus neuraminidase can synthesize its own inhibitor. Structure 1:19-26.
14. Burmeister WE Cusack S, Ruigrok RWH. 1994. Calcium is needed for the thermostability of influeza B virus neuraminidase. J Gen Virol 75:381-388.87.
15. Burnett FM. 1947. Mucins and mucoids in relation to influenza virus action. IV. Inhibition by purified mucoid of infection and haemagglutinin with the virus strain WSE. Aust J Exp Biol Med Sci 26:381-387.
16. Calfee DP, Feng AW, Hussey EK, Lobo M, Hayden FG. 1998. Protective efficacy of reduced frequency dosing of intranasal zanamivir in experimental human influenza. San Diego: ICAAC 24-27 Sept. (Abstr. H-68).
17. Chakraverty et al., 1993. Influenza activity - United States and world-wide, and composition of the 1993-94 influenza vaccine. JAMA 269:1778-1779.
18. Chong AKJ, Pegg MS, von Itzstein M. 1991. Characterisation of an ionisable group involved in the binding and catalysis by sialidase from influenza virus. Biochem Int 24:165-171.
19. Chong AKJ, Pegg MS, Taylor NR, von Itzstein M. 1992. Evidence for a sialyl cation transition state complex in the reaction of sialidase from influenza. Eur J Biochem 207:335-343.
20. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Krauss S, Shortridge KF, Webster RG. 1998. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351:472-477
21. Colman PM. 1989. Influenza virus neuraminidase: Enzyme and antigen. In: Krug RM, editor. The influenza viruses. New York: Plenum Press. p 175-218.
22. Colman PM. 1994. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3:1687-1696.
23. Colman PM. 1997. Virus versus antibody. Structure 5:591-593.
24. Colman PM, Laver WG. 1981. The structure of influenza virus neuraminidase at 5A resolution. In: Structural aspects of recognition and assembly in biological macromolecules. Rehovot, Israel: I.S.S. p 869-872.
25. Colman PM, Varghese JN, Laver WG. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44.
26. Colman PM, Laver WG, Varghese JN, Baker AT, Tullock PA, Air GM, Webster RG. 1987. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. Nature 326: 358-363.
27. Colman PM, Tulip WR, Varghese JN, Tulloch PA, Baker AT, Laver WG, Air GM. 1989. 3-D structures of influenza vims neuraminidase-antibody complexes. Proc R Soc Lond B323:511-518.
28. Compans RW, Dimmock NJ. 1969. An electron microscopic study of single-cycle infection of chick embryo fibroblasts by influenza virus. Virology 39:499.
29. Crennell SJ, Garman EF, Laver WG, Vimr ER, Taylor GL. 1993. Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase. Proc Natl Acad Sci USA 90:9852-9856.
30. Crennell SJ, Garman E, Laver G, Vimr E, Taylor GL. 1994. Crystal structure of Vibro Cholerae neuraminidase reveals dual lectin-like domains in addition to the catalytic domain. Structure 2:535-544.
31. Daniels RS, Downie JC, Hay AJ, Knossow M, Skehel JJ, Wang ML, Wiley DC. 1985. Fusion mutants of the influenza virus haemagglutinin glycoprotein. Cell 40:431-439.
32. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, Ulmer JB, Liu MA. 1995. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1:583-586.
33. Douglas RG Jr. 1990. Drug therapy, prophylaxis and treatment of influenza. N Engl J Med 322:443-450.
34. Drzenick R, Frank H, Rott R. 1968. Electron microscopy of purified influenza virus neuraminidase. Virology 36:703-707.
35. Edmond JD, Johnston RG, Kidd D, Rylance HJ, Sommerville RG. 1966. The inhibition of neuraminidase and antiviral action. Br J Pharmacol Chemother 27:415-426.
36. Eisenberg EJ, Bidgood A, Cundy KC. 1997. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of prodrug GS4104, Antimicrob Agents Chemother 41:1949-1952.
37. Ennis FA, Meager A. 1981. Immune interferon produced to high levels antigenic stimulation of human lymphocytes with influenza virus. J Exp Med 154:1279-1289.
38. Fox JP, Cooney MK, Hall CE, Foy HM. 1982. Influenza virus infections in Seattle families, 1975-1979. II. Pattern of infection of invaded households and relation of age and prior antibody to occurrence of infection by time and age. Am J Epidemiol 116: 228-242.
39. Francis T Jr, Moore AE. 1940. A study of the neurotropic tendency in strains of the virus of epidemic influenza. J Exp Med 72:717-728.
40. Friebolin H, Brossmer R, Keilich G, Ziegler D. 1980. Supp M. 1H-NMR spektroskopischer nachweis der N-acetyl-a-D-neuraminsaure als primares spaltprodukt der neuraminidasen. Hoppe Seyler's Z Physiol Chem 361:697-702.
41. Goodford PJ. 1985. A computational procedure for determining energetically favourable binding sites on biologically important macromolecules. J Med Chem 28:849-857.
42. Gottschalk A. 1957. Neuraminidase: the specific enzyme of influenza virus and vibrio cholerae. Biochem Biophys Acta 23:645-646.
43. Gottschalk A. 1958. Neuraminidase: its substrate and mode of action. Adv Enzymol 20:135-145.
44. Goto H, Kawaoka Y. 1998. A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci USA 95:10224-10228.
45. Griffin JA, Compans RW. 1979. Effect of cytochalsin B on the maturation of enveloped viruses. J Exp Med 150:379-391.
46. Gubareva LV, Bethell R, Hart GJ, Penn CR, Webster RG. 1995. Characterization of mutants of influenza virus selected with 4-guanidino-Neu5Ac2en. Abstracts, 14th Annual Meeting, Am Soc Virol, Austin, Texas W44-1.
47. Gubareva LV, Robinson MJ, Bethell R, Webster RG. 1997. Catalytic framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 71:3385-3390.
48. Gubareva LV, Matrosovich MN, Brenner MK, Bethel RC, Webster RG. 1998. Evidence for Zanamivir resistence in an immunocompromised child infected with influenza B virus. J Infect Diseases 178:1257-1262.
49. Hausmann J, Kretzschmar E, Garten W, Klenk H-D. 1995. N1 neuraminidase of influenza virus A/FPV/Rostock/34 has haemadsorbing activity. J Gen Virol 76:1719-1728.
50. Hay AJ, Thompson CA, Geraghty A, Hayhurst S, Grambas S, Bennett MS. 1993. The role of the M2 protein in influenza virus infection. In: Hannoun C et al., editors. Options for the control of influenza virus II. Amsterdam: Excerpta Medica. p 281-288.
51. Hayden FG. 1993. Update on antiviral agents and viral drug resistance. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious disease. New York: Churchill Livingston. P2(2):3-15.
52. Hayden FG. 1996. Amantidine and rimantidine - clinical aspects. In: Richmond DD, editor. Antiviral drag resistance. Chichester, UK: John Wiley. p 69-77.
53. Hayden FG, Rollins BS, Madren LK. 1994. Anti-influenza activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 25:123-131.
54. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. 1996. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 275:295-299.
55. Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY Nicholson KG, Bohnen AM, Hirst HM, Keene O, Whiteman K. 1997. Efficacy and safety of the neuramimnidase inhibitor Zanamivir in the treatment of influenza virus infections. N Engl J Med 337:874-880.
56. Hayden FG, Atmar R, Schilling M, Johnson C, Poretz D, Parr D, Huson L, Ward P, Mills R. 1998. Safety and efficacy of oral GS4104 in longterm prophylaxis of natural influenza. San Diego: ICAAC 24-27 Sept. (Abstr. LB-6).
57. Hinshaw VS, Webster RG, Turner B. 1980. The perpetuation of orthomyxoviruses and paramyxoviruses in Canadian waterfowl. Can J Microbiol 26:622-629.
58. Hirst GK. 1942. Adsorption of influenza hemagglutinins and virus by red blood cells. J Exp Med 76:1740-1743.
59. Hitte AL, Nayak DP. 1982. Complete nucleotide sequences of the neuraminidase gene of human influenza virus A/WSN/33. J Virol 41:730-734.
60. Janakiraman MN, White CL, Laver WG, Air MA, Luo M. 1994. Structure of influenza virus neuraminidase B/Lee/40 complexed with sialic acid and a dehydro analog at 1.8A-resolution: implications for the catalytic mechanism. Biochemstry 33:8172-8179.
61. Kilbourne ED. 1987. Influenza. New York: Plenum Press.
62. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119:681-690.
63. Kimberlin DW, Crumpacker CS, Straus SE, Biron KK, Drew WL, Hayden FG, McKinlay M, Richman DD, Whitley RJ. 1995. Antiviral resistance in clinical practice. Antiviral Res 26:423-438.
64. Klenk E, Faillard H, Lempfrid H, 1955. Uber die enzymatishe Wirkung von Ifluenza. Z Physiol Chem 301:235-246.
65. Kraulis PJ. 1991. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J Appl Cryst D50:869-873.
66. Kunkel TA, Roberts JD, Zakaur RA. 1987. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol 154:369-382.
67. Lamb RA. 1989. Genes and proteins of the influenza virus. In: Krug RM, editor. The influenza viruses. New York: Plenum Press. p 1-87.
68. Laver WG. 1963. The structure of influenza virus 3. Disruption of the virus particle and separation of neuraminidase activity. Virology 20:251-262.
69. Laver WG. 1978. Crystallization and peptide maps of neuraminidase "heads" from H2N2 and H3N2 influenza virus strains. Virology 86:78-87.
70. Laver WG, Valentine RC. 1969. Morphology of the isolated hemagglutinin and neuraminidase subunits of influenza virus. Virology 38:105-119.
71. Laver WG, Colman PM, Webster RG, Hinshaw VS, Air GM. 1984. Influenza virus neuraminidase with hemagglutinin activity. Virology 137:314-323.
72. Lentz MR, Webster RG, Air GM. 1987. Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism. Biochemistry 26:5351-5358.
73. Li S, Schulman J, Itamura S, Palase P. 1993. Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus. J Virol 67:6667-6673.
74. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB. 1998. Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071. Antimicrob Agents Chemother 42:647-653.
75. Liu C, Air GM. 1993. Selection and characterization of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neuraminidase genes. Virology 194:403-407.
76. Liu C, Eichelberger MC, Compans RW, Air GM. 1995. Influenza type A viurs neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 69:1099-1106.
77. Luo M, Jedrzejas MJ, Singh S, White CL, Brouillette WJ, Air GM, Laver WG. 1995. Benzoic acid inhibitors of influenza virus neuraminidase. Acta Crystallogr D51:504-510.
78. Madren LK, Shipman C, Hayden FG. 1995. In vitro inhibitory effects of combinations of anti-influenza agents. Antiviral Chem Chemother 6(2):109-113.
79. Malby RL, Tulip WR, Harley VR, McKimm-Breschkin JL, Laver WG, Webster RG, Colman PM. 1994. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure 2:733-746.
80. McKimm-Breschkin JL, Marshall D, Penn CR. 1994. Phenotypic changes observed in influenza viruses passaged in 4-amino or 4-guanidino-Neu5Ac2en in vitro. Abstracts, 9th International Conference on Negative Strand Viruses, Estoril, Portugal, p 260.
81. McKimm-Breschkin JL, Blick TJ, Sarasrabudhe AV, Tiong T, Marshall D, Hart GJ, Bethell RC, Penn CR. 1996. Generation and characterisation of variants of the NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 40:40-46.
82. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, Bethell RC, Varghese JN. 1998. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en derivatives. J Virol 72:2456-2462.
83. Meindl P, Tuppy H. 1969. 2-Deoxy-2,3-dehydrosialic acids. I. Synthesis and properties of 2-deoxy-2,3-dehydro-N-acetylneuraminic acids and their methyl esters. Monatsh Chem. 100:1295-1306.
84. Meindl P, Bodo G, Palase P, Schulman J, Tuppy H. 1974. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic. Virology 58:457-463.
85. Mendel DB, Tai CY, Escarpe PA, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42:640-646
86. Miller CA, Wang P, Flashner M. 1978. Mechanism of Arthro-bacter sialophilus neuraminidase: the binding of substrates and transition state analogues. Biochem Biophys Res Commun 83:1479-1487.
87. Monto AS, Ohmir Se, Hornbuckle K, Pearce CL. 1995. Safety and efficacy of long term use of rimantadine for prophylaxis of type 1 influenza in nursing homes. Antimicrob Agents Chemother 39:2224-2228.
88. Monto AS, Robinson DP, Herlocher L, Hinson JM, Elliott M, Keene O. 1998. Efficacy and safety of zanamivir in prevention of influenza among healthy adults. San Diego: ICAAC 24-27 Sept. (Abstr. LB-7).
89. Murphy JS, Bang FB. 1952. Observations with the electron microscope on cells of chick chorio-allantoic membrane infected with influenza virus. J Exp Med 95:259.
90. Murphy BR, Webster RG. 1990. Orthomyxovirus. In: Fields BN, Knipe DM, editors. Virology. New York: Raven Press. p 1091-1152.
91. Nagai T, Yamada H. 1994. In vivo anti-influenza virus activity of Kampo (Japanese herbal) medicine "Sho-seiryu-to" and its mode of action. Int J Immunopharmacol 16(8):605-613.
92. Nagai T, Miyaichi Y, Tomimori T, Suzuki Y, Yamada H. 1990. Inhibition of influenza virus sialidase and anti-influenza virus activity by plant flavonoids. Chem Pharm Bull 38(5):1329-1332.
93. Nicholls A, Sharp K, Honig B. 1991. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11:281-296.
94. Nohle U, Beau J-M, Schauer R. 1982. Uptake, metabolism and excretion of orally and intravenously administered, double-labeled N-glycoloylneuraminic and single-labeled 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat. Eur J Biochem 126:543-548.
95. Nuss JM, Air GM. 1991. Transfer of the hemagglutinm activity of influenza virus neuraminidase subtype N9 into N2 neuraminidase background. Virology 183:496-504.
96. Osterhaus ADME, Tisdale M, Elliot M. 1998. Double blind randomised trial of zanamivir in the treatment of acute influenza -clinical and virological efficacy results. San Diego: ICAAC 24-27 Sept. (Abstr. H-67).
97. Palese P, Compans RW. 1976. Inhibition of influenza virus replication in tissue culture 2-deoxy-2,3-dehydro-N-trifluroacetylneuraminic acid. FANA: mechanism of action. J Gen Virol 33:159-163.
98. Palese P, Schulman JL. 1977. Inhibitors of viral neuraminidase as potential antiviral drugs. In: Chemoprophylaxis and virus infections of the upper respiratory tract, vol 1. Boca Raton, FL: CRC Press. p 189-205.
99. Palese P, Tobita K, Ueda M, Compans RW. 1974a. Characterisation of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61:397-410.
100. Palese P, Schulman JL, Bodo G, Meidl P. 1974b. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluroacetylneuraminic acid. FANA Virol 59:490-498.
101. Pearlman DA, Case DA, Caldwell J, Seibel G, Singh UC, Weiner PK, Kollman PA. 1990. AMBER 4.0 San Franscisco, CA: University of California.
102. Pinto LH, Holsinger LJ, Lamb RA. 1992. Influenza virus M2 protein has ion channel activity. Cell 69:517-528.
103. Rogers GN, Paulson JC. 1983. Receptor determinants of human and animal influenza virus isolates: difference in receptor specificity of the H3 haemagglutinin based on species of origin. Virology 127:361-373.
104. Ryan DM, Ticehurst J, Dempsey MH, Penn CR. 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase. Antimicrob Chem Chemother 38(10):2270-2275.
105. Sahasrabudhe A, Lawrence L, Epa VC, Varghese JN, Colman PM, McKimm-Breschkin JL. 1998. Substrate, inhibitor, or antibody stabilises the Glu 119 Gly mutant influenza virus neuraminidase. Virology 247:14-21.
106. Skehel JJ. 1974. The origin of pandemic influenza virus. Symp Soc Gen Microbiol 24:321-342.
107. Slemons RD, Johnson DC, Osborn JS, Hayes F. 1974. Type A influenza viruses iosloated from wild free-flying ducks in California. Avian Dis 18:119-125.
108. Smith FI, Palese P. 1989. Variation in influenza virus genes. Epidemiological, pathogenic, and evolutionary consequences. In: Krug RM, editor. The influenza viruses. New York: Plenum Press, p 319-359.
109. Smith W, Andrewes CH, Laidlaw PP. 1933. A virus obtained from influenza patients. Lancet 2:66-68.
110. Smith PW, Sollis SL, Howes PD, Cherry PC, Cobley KN, Taylor H, Whittington AR, Scicinski J, Bethell RC, Taylor N, Skarzynski T, Cleasby A, Singh O, Wonacott A, Varghese J, Colman P. 1996. Novel inhibitors of influenza sialidases related to GG167. Structure-activity, crystallographic and molecular dynamics studies with 4H-pyran-2-carboxylic acid 6-carboxamides. Bioorg Med Chem Lett 6(24):2931-2936.
111. Sollis SL, Smith PW, Howes PD, Cherry PC, Bethell RC. 1996. Novel inhibitors of influenza sialidase related to GG167. Synthesis of 4-amino and 4-guanidino-4H-pyran-2-carboxylic acid-6-propylamides; selective inhibitors of influenza A virus sialidase. Bioorg Med Chem Lett 6(15): 1805-1808.
112. Sprenger MJW, Beyer WEP, Kempen BM, Mulder PGH, Masurel N. 1993. Risk factors for influenza mortality. In: Hannoun C et al., editors. Options for the control of influenza virus II. Amsterdam: Excerpta Medica. p 15-23.
113. Srange KC, Little DW, Blarnik B. 1991. Adverse reactions to amantadine prophylaxis of influenza in a retirement home. J Am Geriatr Soc 33:700-705.
114. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K, Cox N. 1998. Characterisation of an avian influenza A (H5N1) vims isolated from a child with fatal respiratory illness. Science 279:393-396.
115. Suzuki Y, Sato K, Kiso M, Hasegawa A. 1990. New ganglioside analogs that inhibit influenza virus sialidase. Glycoconjugate J 7:349-356.
116. Taylor NR, von Itzstein M. 1994. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J Med Chem 37:616-624.
117. Taylor NR, Cleasby A, Singh O, Skarzynski T, Wanacott A, Smith PW, Sollis SL, Howes PD, Cherry PC, Bethell R, Colman P, Varghese J. 1998. Dihydropyran carboxamides related to Zanamivir. A new series of inhibitors of influenza virus sialidases. Part 2: A crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza types A and B. J Med Chem 41:798-807.
118. Thomas GP, Forsyth M, Penn CR, McCauley JW. 1994. Inhibition of growth of influenza virus in vitro by 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Antiviral Res 24:351-356.
119. Treanor JJ, Vrooman PS, Hayden FG, Kinnersley N, Ward P, Mills RG. 1998. Efficacy of oral GS4104 in treating acute influenza. San Diego: ICAAC 24-27 Sept. (Abstr. LB-4).
120. Tulip WG, Varghese JN, Baker AT, van Donkelaar A, Laver WG, Webster RG, Colman PM. 1992a. Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants. J Mol Biol 221:487-497.
121. Tulip WG, Varghese JN, Laver WG, Webster RG, Colman PM. 1992b. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J Mol Biol 227:122-148.
122. Tyrrell DAJ. 1980. Influenza vaccines. Phil Trans R Soc Lond B288:449-460.
123. Varghese JN. 1997. The design of anti-influenza virus drugs from the X-ray molecular structure of influenza virus neuraminidase. In: Veerapandian P, editor. Structure based drug design: diseases, targets, techniques and developments, vol 1. New York: Marcel Dekker. p 459-486.
124. Varghese JN, Colman PM. 1991. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2Å resolution. J Mol Biol 221:473-486.
125. Varghese JN, Laver WG, Colman PM. 1983. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9A resolution. Nature 303:35-40.
126. Varghese JN, Webster RG, Laver WG, Colman PM. 1988. The three-dimensional structure of an escape mutant of the neuraminidase of influenza virus A/Tokyo/3/67. J Mol Biol 200:201-203.
127. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. 1992. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332.
128. Varghese JN, Epa VC, Colman PM. 1995. Three-dimensional structure of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 4:1081-1087.
129. Varghese JN, Colman PM, van Donkelaar A, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL. 1997. Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidase. Proc Natl Acad Sci USA 94:11808-11812.
130. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL, Colman PM. 1998. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6:735-746.
131. von Itzstein M, Wu W-Y, Kok GB, Pegg MS, Dyson JC, Jin B, VanPhan T, Symthe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, Penn CR. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
132. von Itzstein M, Wu W-Y, Jin B. 1994. The synthesis 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus inhibitor. Carbohydr Res 259:301-305.
133. Wagh PV, Bahl OP. 1981. Sugar residues on proteins. Crit Rev Biochem 307-377.
134. Ward CW. 1981. Structure of influenza virus hemagglutinin. Curr Top Microbiol Immunol 94/95:1-74.
135. Ward CW, Elleman TC, Azad AA. 1982. Amino acid sequence of the pronase-released heads of neuraminidase subtype N2 from the Asian strain A/Tokyo/3/67 of influenza virus. Biochem J 207:91-95.
136. Ward CW, Murry JM, Roxburgh CM, Jackson DC. 1983. Chemical and antigenic characterisation of the carbohydrate side chains of an Asian (N2) influenza virus neuraminidase, Virology 126:370-375.
137. Webster RG, Laver WG. 1975. Antigenic variation in influenza viruses. In: Kilboume ED, editor. Influenza virus and influenza. New York: Academic Press, p 269-314.
138. Webster RG, Air GM, Metzger DW, Colman PM, Varghese JN, Baker AT, Laver WG. 1987. Antigenic structure and variation in an influenza N9 neuraminidase. J Virol 61:2910-2916.
139. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. 1992. Evolution and ecology of influenza A viruses. Microbiol Rev 56:152-179.
140. Webster RG, Schafer JR, Suss J, Bean WJ Jr, Kawaoko Y. 1993. Evolution and ecology of influenza viruses. In: Hannoun C et al., editors. Options for the control of influenza virus II. Amsterdam: Excerpta Medica. p 177-185.
141. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. 1988. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333:426-431.
142. White DO. 1974. Influenza viral proteins: identification and synthesis. Curr Top Microbiol Immunol 63:1-48.
143. Wintermeyer SM, Nahata MC. 1995. Rimantadine: a clinical perspective. Ann Pharmacother 29:299-310.
144. Woods JM, Bethell RC, Coates JAV Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcott SM, Penn CR. 1993. 4-Guanidino-2-4-dideoxy-2,3-dehydro-n-acerylneurammic acid is a highly effective inhibitor both of the Sialidase (Neuraminidase) and growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 37:1473-1479.
145. Wright CE, Laver WG. 1978. Preliminary crystallographic data for influenza virus neuraminidase 'heads.' J Mol Biol 120: 133-136.
146. Yeun KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KE Cheung PT, To WK, Ho ET, Sung R, Cheng AE 1998. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351:467-471.